Printer Friendly
The Free Library
21,435,892 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Theragenics Corp. names Otis Brawley, M.D. as director.

ATLANTA--(BUSINESS WIRE)--Feb. 16, 1995--Theragenics Corp. (NASDAQ NASDAQ
 in full National Association of Securities Dealers Automated Quotations

U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on
:THRX) today announced the appointment of Otis Webb Brawley, M.D., to the Board of Directors.

Brawley, a Board-Certified Medical Oncologist medical oncologist  Oncology An oncologist who diagnoses and treats cancer with chemotherapy, hormones, biologicals, or immunologic agents; the MO becomes a cancer Pt's de facto primary care giver, and coordinates treatment provided by other specialists. , has been Program Director of the Community Oncology and Rehabilitation Branch, Early Detection and Community Oncology Program, a Division of Cancer Prevention and Control of the National Cancer Institute since 1990. Brawley has also been a Commissioned Officer of the U.S. Public Health Service since 1989 and Tenured ten·ured  
adj.
Having tenure: tenured civil servants; tenured faculty.

Adj. 1. tenured
 with the Research Officer Group since February 1994.

Dr. Brawley's professional activities have included: National Cancer Institute (NCI See Liberate. ) Coordinator and Project Officer of the Prostate Cancer Prevention Trial, NCI Coordinator of the Minority Based Community Clinical Oncology Program, and coauthor and associate investigator in several protocols approved by the National Institutes of Health Clinical Center Investigational Review Committee. Brawley has received such distinguished honors as the Public Health Service Commendation in 1993; National Cancer Institute and the Equal Employment Opportunity Officer's Commendation in 1991 and 1993. Having coauthored over 21 publications, he is a sought after lecturer on principles of cancer treatments specifically as it relates to prostate cancer. Brawley also reviews for several publications such as: the New England Journal of Medicine The New England Journal of Medicine (New Engl J Med or NEJM) is an English-language peer-reviewed medical journal published by the Massachusetts Medical Society. It is one of the most popular and widely-read peer-reviewed general medical journals in the world. , the Journal of the National Cancer Institute, the Journal of the U.S. Public Health Service, and Contemporary Oncology.

Commenting on his appointment, Charles Klimkowski, Chairman of the Board said, ``Dr. Brawley adds a new and exciting dimension to the expertise of the Board of Directors. He is an excellent source of firsthand experience with this devastating dev·as·tate  
tr.v. dev·as·tat·ed, dev·as·tat·ing, dev·as·tates
1. To lay waste; destroy.

2. To overwhelm; confound; stun: was devastated by the rude remark.
 disease known as prostate cancer. I am delighted to have him join the board and welcome his help in guiding the company into its next phase of growth.''

Theragenics Corp. is the manufacturer of TheraSeed (R) - palladium-103 a rice-sized radioactive source used in the treatment of localized prostate cancer through a one-time, minimally-invasive procedure. The Company's common stock is traded on the NASDAQ Stock Market Nasdaq stock market

The first electronic stock market listing over 5000 companies. The Nasdaq stock market comprises two separate markets, namely the Nasdaq National Market, which trades large, active securities and the Nasdaq Smallcap Market that trades emerging growth companies.
 under the symbol THRX.

CONTACT: Theragenics Corp., Atlanta

Ron Warren, 800/998-THRX (8479)
COPYRIGHT 1995 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1995, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Feb 16, 1995
Words:336
Previous Article:Net income increases to $488,927 on sales of $2,559,121 for 1st half Fiscal 1995; LANNETT ANNOUNCES SECOND CONSECUTIVE PROFITABLE QUARTER, FISCAL...
Next Article:Eventus now shipping WatchWorks 3.0; provides comprehensive event-monitoring and expert advice for ORACLE databases.
Topics:



Related Articles
Theragenics Corp. names Charles Klimkowski chairman to succeed outgoing chairman John V. Herndon.
Theragenics Corp. names Otis Brawley, M.D. as director.
Theragenics Corp. reports revenue and earnings for second quarter 1996.
Theragenics Enters Agreement to Purchase Four Additional Cyclotrons.
Theragenics Corporation Reports Record Revenue and Earnings for First Quarter 1998.
Theragenics Announces TheraSeed Distribution Agreement With Nycomed Amersham.
Theragenics Expands TheraSeed Distribution Worldwide.
AVC CAN'T KEEP UP WITH JONES : S'WESTERN 20 AVC 17.
HITTING THE RIGHT CORD: GUITAR MAKER FENDER REGAINS FORMER LUSTROUS IMAGE.
LOCAL CHRISTIAN RADIO SENDS ITS MESSAGE AROUND THE WORLD.

Terms of use | Copyright © 2013 Farlex, Inc. | Feedback | For webmasters | Submit articles